FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

FOUNTAINHEAD CAPITAL MANAGEMENT LTD		 2. Issuer Name and Ticker or Trading Symbol

VYCOR MEDICAL INC [ VYCO ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

17 BOND STREET, ST HELIER		 3. Date of Earliest Transaction (MM/DD/YYYY)

3/31/2020
(Street)

JERSEY CHANNEL ISLANDS, X0 JE2 3NP
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 3/31/2020  J(1)  535714 A$0.21 14983381 D  
Series D Preferred Stock         188363 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option $0.27           6/30/2018 (2)6/30/2021 (2)Common Stock 660000  660000 D  
Explanation of Responses:
(1) Shares issued on account of accrued consultancy fees as of March 31, 2020.
(2) Issued pursuant to Fountainhead Consultancy Agreement, and subject to performance vesting conditions.
Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
FOUNTAINHEAD CAPITAL MANAGEMENT LTD
17 BOND STREET
ST HELIER
JERSEY CHANNEL ISLANDS, X0 JE2 3NP
X
Signatures
/s/ Claire Louise Farrow, Director4/6/2020
**Signature of Reporting PersonDate
Vycor Medical (QB) (USOTC:VYCO)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024 Click aqui para mais gráficos Vycor Medical (QB).
Vycor Medical (QB) (USOTC:VYCO)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024 Click aqui para mais gráficos Vycor Medical (QB).